Of the 996 patients who had previously failed at least one biologic agent, 22.8% (n = 227) received abatacept as monotherapy and 77.2% (n = 769) received abatacept in combination with another DMARD, of whom 61.0% (n = 469) received abatacept in combination with MTX.
Results are now available for 479 adult patients who received etanercept as monotherapy for more than 1 year, 420 patients who received the drug for more than 2 years, 164 patients who received the drug for more than 3 years, and 12 patients who received the drug for more than 4 years [ 19].
Sixteen patients received platins-pemetrexed as first-line treatment for NSCLC and 46 received pemetrexed as monotherapy in second and subsequent lines.
Forty-three patients from the USA (20/449 (4.5%) washout and 23/597 (3.9%) direct-switch patients) were not receiving background non-biological DMARD therapy during the 6-month study period and thus received abatacept as monotherapy.
Sixteen of the 25 patients received daily injections of anakinra (100 mg/day) subcutaneously as adjunct therapy together with a DMARD and nine patients received anakinra as monotherapy.
Twenty-four subjects received ficlatuzumab as monotherapy (2 mg kg 1, n=3; 5 mg kg 1, n=3; 10 mg kg 1, n=3; 20 mg kg 1, n=15), and 13 subjects received the ficlatuzumab/erlotinib combination.
The incidence of mild hypoglycemia in patients who received EQW as monotherapy or in combination with metformin or thiazolidinediones was low, although it was higher in patients who received concomitant treatment with a sulfonylurea.
Twenty-two patients (25.6%) received steroids as monotherapy.
One patient (3.1%) received levofloxacin as monotherapy.
